Comment le bénéfice par action récent de VRAX se compare-t-il aux attentes ?
Comment les revenus de Virax Biolabs Group Ltd VRAX se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Virax Biolabs Group Ltd ?
Quel est le score de qualité des bénéfices pour Virax Biolabs Group Ltd ?
Quand Virax Biolabs Group Ltd publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Virax Biolabs Group Ltd ?
Virax Biolabs Group Ltd a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$0.277
Prix d'ouverture
$0.28
Plage de la journée
$0.2701 - $0.2899
Plage de 52 semaines
$0.255 - $2.29
Volume
72.3K
Volume moyen
5.2M
BPA (TTM)
-1.25
Rendement en dividend
--
Capitalisation boursière
$1.8M
Qu’est-ce que VRAX ?
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).